Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
H1N1 challenge results in rapid recall of stem-specific immunity in HA stem nanoparticle–vaccinated newborn monkeys
Kali F. Crofts, Beth C. Holbrook, Courtney L. Page, Maya Sangesland, Masaru Kanekiyo, Martha Alexander-Miller
Kali F. Crofts, Beth C. Holbrook, Courtney L. Page, Maya Sangesland, Masaru Kanekiyo, Martha Alexander-Miller
View: Text | PDF
Research Article Immunology Infectious disease

H1N1 challenge results in rapid recall of stem-specific immunity in HA stem nanoparticle–vaccinated newborn monkeys

  • Text
  • PDF
Abstract

Primary exposure to influenza antigens during infancy shapes the humoral response to subsequent exposures. Development of a universal vaccine approach to protect newborns against influenza would represent a major step forward. In our previous study, we showed vaccination of newborn African green monkeys (AGMs) with an adjuvanted hemagglutinin (HA) stem nanoparticle induced robust IgG responses with broad recognition across HAs. Here, we examined the cellular responses in the lung-draining lymph node of these vaccinated newborn AGMs following challenge with a heterologous H1N1 virus. Our results show that vaccination is associated with early HA stem IgG+ B cell and antibody-secreting cell responses following infection, consistent with a rapidly recalled memory response. In addition, there was evidence of an increase in both HA stem– and head–specific plasma cells in vaccinated animals, suggesting a vaccine-engendered benefit for novel antibodies targeting HA epitopes. Finally, challenge was associated with preferential increases in antibodies that cross-react with H5 HA, suggesting improved protection against this divergent strain. Overall, these findings indicate that HA stem with AddaVax as adjuvant generates a stem-specific cross-reactive memory pool in newborn AGMs with the potential to be rapidly recalled upon infection.

Authors

Kali F. Crofts, Beth C. Holbrook, Courtney L. Page, Maya Sangesland, Masaru Kanekiyo, Martha Alexander-Miller

×

Figure 5

H1N1 challenge of H1ssF+AddaVax-vaccinated infant AGMs preferentially promotes increases in H5-binding IgG on day 7 p.c.

Options: View larger image (or click on image) Download as PowerPoint
H1N1 challenge of H1ssF+AddaVax-vaccinated infant AGMs preferentially pr...
Group 1 and group 2 HA–specific IgG binding was measured in the plasma on day 41/day 45 p.b. and day 7 p.c. Group 1 HA subtypes include A/New Caledonia/20/1999 (H1 1999 NC99) (A), A/California/07/2009 (H1 2009 Ca09) (B), A/Vietnam/1204/2004 (H5 2004 VI) (C), A/Singapore/1/1957 (H2 1957 SI) (D), and A/Hong Kong/33982/2009 (H9 2009 HK) (E). Group 2 HA subtypes include A/Wisconsin/67/2005 (H3 2005 WI) (F) and A/Anhui/1/2013 (H7 2013 AN) (G). The dotted line represents the limit of detection for the assay. (H) The average representation of each HA on day 7 p.c. for each animal. Threshold titer (TT) was defined as the highest dilution resulting in an OD450 greater than 3 times the assay background. Ctrl (PBS/Luc mRNA black symbols and H1ssF blue symbols, n = 9), H1ssF+AddaVax (red symbols, n = 8). Data represent the median. Statistical significance was determined using a 1-way ANOVA with Tukey’s post hoc analysis. Not significant (NS) P > 0.05, **P < 0.01, ***P < 0.001, ****P ≤ 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts